PMC:7417114 / 17404-18941 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T85","span":{"begin":445,"end":454},"obj":"Body_part"},{"id":"T86","span":{"begin":790,"end":794},"obj":"Body_part"},{"id":"T87","span":{"begin":884,"end":888},"obj":"Body_part"},{"id":"T88","span":{"begin":1050,"end":1054},"obj":"Body_part"},{"id":"T89","span":{"begin":1133,"end":1137},"obj":"Body_part"}],"attributes":[{"id":"A85","pred":"fma_id","subj":"T85","obj":"http://purl.org/sig/ont/fma/fma67180"},{"id":"A86","pred":"fma_id","subj":"T86","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A87","pred":"fma_id","subj":"T87","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A88","pred":"fma_id","subj":"T88","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A89","pred":"fma_id","subj":"T89","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"The ABL inhibitors, imatinib and dasatinib, were identified in a screen as inhibitors of both SARS-CoV and MERS-CoV replication, and nilotinib was identified as an inhibitor of only SARS-CoV, in vitro (27). Investigation of the mechanism for imatinib against SARS-CoV and MERS-CoV revealed inhibition of the early stages of the virus life cycle, and inhibition of viral replication through blocking the fusion of the coronavirus virion with the endosomal membrane (28) (29). Importantly, authors show that targeted knockdown of ABL2, however not ABL1, significantly inhibited SARS-CoV and MERS-CoV replication/entry in vitro (29). The relatively high, albeit minimally toxic, μM range concentrations of imatinib and dasatinib required to inhibit SARS-CoV and MERS-CoV in the aforementioned cell-based studies may be attributable to experimental factors such as drug resistance of the cell lines used as tools for propagating the viruses (27) (29), and thus in vivo testing would be needed to determine optimal dosing. It is worth noting that in many cell-based assays measuring drug effects on virus titer, the antiviral activity is cell-type dependent, and there is also variability depending on which virus strain is used. Recent, unpublished results, reported as a preprint, suggest that imatinib inhibits SARS-CoV-2 in vitro, among 17 other FDA-approved drugs with IC50 values similar to those observed for SARS-CoV and MERS-CoV; concentrations showing antiviral activity were not cytotoxic (BioRxiv, 2020, 10.1101/2020.03.25.008482)"}

LitCovid-PD-MONDO

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T141","span":{"begin":4,"end":7},"obj":"Disease"},{"id":"T142","span":{"begin":94,"end":102},"obj":"Disease"},{"id":"T143","span":{"begin":182,"end":190},"obj":"Disease"},{"id":"T144","span":{"begin":259,"end":267},"obj":"Disease"},{"id":"T145","span":{"begin":576,"end":584},"obj":"Disease"},{"id":"T146","span":{"begin":746,"end":754},"obj":"Disease"},{"id":"T147","span":{"begin":1309,"end":1317},"obj":"Disease"},{"id":"T148","span":{"begin":1411,"end":1419},"obj":"Disease"}],"attributes":[{"id":"A141","pred":"mondo_id","subj":"T141","obj":"http://purl.obolibrary.org/obo/MONDO_0008692"},{"id":"A142","pred":"mondo_id","subj":"T142","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A143","pred":"mondo_id","subj":"T143","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A144","pred":"mondo_id","subj":"T144","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A145","pred":"mondo_id","subj":"T145","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A146","pred":"mondo_id","subj":"T146","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A147","pred":"mondo_id","subj":"T147","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A148","pred":"mondo_id","subj":"T148","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"The ABL inhibitors, imatinib and dasatinib, were identified in a screen as inhibitors of both SARS-CoV and MERS-CoV replication, and nilotinib was identified as an inhibitor of only SARS-CoV, in vitro (27). Investigation of the mechanism for imatinib against SARS-CoV and MERS-CoV revealed inhibition of the early stages of the virus life cycle, and inhibition of viral replication through blocking the fusion of the coronavirus virion with the endosomal membrane (28) (29). Importantly, authors show that targeted knockdown of ABL2, however not ABL1, significantly inhibited SARS-CoV and MERS-CoV replication/entry in vitro (29). The relatively high, albeit minimally toxic, μM range concentrations of imatinib and dasatinib required to inhibit SARS-CoV and MERS-CoV in the aforementioned cell-based studies may be attributable to experimental factors such as drug resistance of the cell lines used as tools for propagating the viruses (27) (29), and thus in vivo testing would be needed to determine optimal dosing. It is worth noting that in many cell-based assays measuring drug effects on virus titer, the antiviral activity is cell-type dependent, and there is also variability depending on which virus strain is used. Recent, unpublished results, reported as a preprint, suggest that imatinib inhibits SARS-CoV-2 in vitro, among 17 other FDA-approved drugs with IC50 values similar to those observed for SARS-CoV and MERS-CoV; concentrations showing antiviral activity were not cytotoxic (BioRxiv, 2020, 10.1101/2020.03.25.008482)"}

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T187","span":{"begin":63,"end":64},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T188","span":{"begin":202,"end":204},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T189","span":{"begin":328,"end":333},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T190","span":{"begin":455,"end":463},"obj":"http://purl.obolibrary.org/obo/UBERON_0000158"},{"id":"T191","span":{"begin":528,"end":532},"obj":"http://purl.obolibrary.org/obo/CLO_0053407"},{"id":"T192","span":{"begin":790,"end":794},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T193","span":{"begin":884,"end":894},"obj":"http://purl.obolibrary.org/obo/CLO_0000031"},{"id":"T194","span":{"begin":929,"end":936},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T195","span":{"begin":938,"end":940},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T196","span":{"begin":965,"end":972},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T197","span":{"begin":1050,"end":1054},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T198","span":{"begin":1094,"end":1099},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T199","span":{"begin":1121,"end":1129},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T200","span":{"begin":1133,"end":1142},"obj":"http://purl.obolibrary.org/obo/CL_0000000"},{"id":"T201","span":{"begin":1203,"end":1208},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T202","span":{"begin":1266,"end":1267},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T203","span":{"begin":1467,"end":1475},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"}],"text":"The ABL inhibitors, imatinib and dasatinib, were identified in a screen as inhibitors of both SARS-CoV and MERS-CoV replication, and nilotinib was identified as an inhibitor of only SARS-CoV, in vitro (27). Investigation of the mechanism for imatinib against SARS-CoV and MERS-CoV revealed inhibition of the early stages of the virus life cycle, and inhibition of viral replication through blocking the fusion of the coronavirus virion with the endosomal membrane (28) (29). Importantly, authors show that targeted knockdown of ABL2, however not ABL1, significantly inhibited SARS-CoV and MERS-CoV replication/entry in vitro (29). The relatively high, albeit minimally toxic, μM range concentrations of imatinib and dasatinib required to inhibit SARS-CoV and MERS-CoV in the aforementioned cell-based studies may be attributable to experimental factors such as drug resistance of the cell lines used as tools for propagating the viruses (27) (29), and thus in vivo testing would be needed to determine optimal dosing. It is worth noting that in many cell-based assays measuring drug effects on virus titer, the antiviral activity is cell-type dependent, and there is also variability depending on which virus strain is used. Recent, unpublished results, reported as a preprint, suggest that imatinib inhibits SARS-CoV-2 in vitro, among 17 other FDA-approved drugs with IC50 values similar to those observed for SARS-CoV and MERS-CoV; concentrations showing antiviral activity were not cytotoxic (BioRxiv, 2020, 10.1101/2020.03.25.008482)"}

LitCovid-PD-CHEBI

LitCovid-PubTator

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T27","span":{"begin":861,"end":876},"obj":"Phenotype"}],"attributes":[{"id":"A27","pred":"hp_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/HP_0020174"}],"text":"The ABL inhibitors, imatinib and dasatinib, were identified in a screen as inhibitors of both SARS-CoV and MERS-CoV replication, and nilotinib was identified as an inhibitor of only SARS-CoV, in vitro (27). Investigation of the mechanism for imatinib against SARS-CoV and MERS-CoV revealed inhibition of the early stages of the virus life cycle, and inhibition of viral replication through blocking the fusion of the coronavirus virion with the endosomal membrane (28) (29). Importantly, authors show that targeted knockdown of ABL2, however not ABL1, significantly inhibited SARS-CoV and MERS-CoV replication/entry in vitro (29). The relatively high, albeit minimally toxic, μM range concentrations of imatinib and dasatinib required to inhibit SARS-CoV and MERS-CoV in the aforementioned cell-based studies may be attributable to experimental factors such as drug resistance of the cell lines used as tools for propagating the viruses (27) (29), and thus in vivo testing would be needed to determine optimal dosing. It is worth noting that in many cell-based assays measuring drug effects on virus titer, the antiviral activity is cell-type dependent, and there is also variability depending on which virus strain is used. Recent, unpublished results, reported as a preprint, suggest that imatinib inhibits SARS-CoV-2 in vitro, among 17 other FDA-approved drugs with IC50 values similar to those observed for SARS-CoV and MERS-CoV; concentrations showing antiviral activity were not cytotoxic (BioRxiv, 2020, 10.1101/2020.03.25.008482)"}

LitCovid-PD-GO-BP

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T50","span":{"begin":350,"end":381},"obj":"http://purl.obolibrary.org/obo/GO_1903901"},{"id":"T51","span":{"begin":364,"end":381},"obj":"http://purl.obolibrary.org/obo/GO_0019079"},{"id":"T52","span":{"begin":364,"end":381},"obj":"http://purl.obolibrary.org/obo/GO_0019058"},{"id":"T53","span":{"begin":861,"end":876},"obj":"http://purl.obolibrary.org/obo/GO_0042493"}],"text":"The ABL inhibitors, imatinib and dasatinib, were identified in a screen as inhibitors of both SARS-CoV and MERS-CoV replication, and nilotinib was identified as an inhibitor of only SARS-CoV, in vitro (27). Investigation of the mechanism for imatinib against SARS-CoV and MERS-CoV revealed inhibition of the early stages of the virus life cycle, and inhibition of viral replication through blocking the fusion of the coronavirus virion with the endosomal membrane (28) (29). Importantly, authors show that targeted knockdown of ABL2, however not ABL1, significantly inhibited SARS-CoV and MERS-CoV replication/entry in vitro (29). The relatively high, albeit minimally toxic, μM range concentrations of imatinib and dasatinib required to inhibit SARS-CoV and MERS-CoV in the aforementioned cell-based studies may be attributable to experimental factors such as drug resistance of the cell lines used as tools for propagating the viruses (27) (29), and thus in vivo testing would be needed to determine optimal dosing. It is worth noting that in many cell-based assays measuring drug effects on virus titer, the antiviral activity is cell-type dependent, and there is also variability depending on which virus strain is used. Recent, unpublished results, reported as a preprint, suggest that imatinib inhibits SARS-CoV-2 in vitro, among 17 other FDA-approved drugs with IC50 values similar to those observed for SARS-CoV and MERS-CoV; concentrations showing antiviral activity were not cytotoxic (BioRxiv, 2020, 10.1101/2020.03.25.008482)"}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T106","span":{"begin":0,"end":206},"obj":"Sentence"},{"id":"T107","span":{"begin":207,"end":474},"obj":"Sentence"},{"id":"T108","span":{"begin":475,"end":630},"obj":"Sentence"},{"id":"T109","span":{"begin":631,"end":1017},"obj":"Sentence"},{"id":"T110","span":{"begin":1018,"end":1224},"obj":"Sentence"},{"id":"T111","span":{"begin":1225,"end":1537},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The ABL inhibitors, imatinib and dasatinib, were identified in a screen as inhibitors of both SARS-CoV and MERS-CoV replication, and nilotinib was identified as an inhibitor of only SARS-CoV, in vitro (27). Investigation of the mechanism for imatinib against SARS-CoV and MERS-CoV revealed inhibition of the early stages of the virus life cycle, and inhibition of viral replication through blocking the fusion of the coronavirus virion with the endosomal membrane (28) (29). Importantly, authors show that targeted knockdown of ABL2, however not ABL1, significantly inhibited SARS-CoV and MERS-CoV replication/entry in vitro (29). The relatively high, albeit minimally toxic, μM range concentrations of imatinib and dasatinib required to inhibit SARS-CoV and MERS-CoV in the aforementioned cell-based studies may be attributable to experimental factors such as drug resistance of the cell lines used as tools for propagating the viruses (27) (29), and thus in vivo testing would be needed to determine optimal dosing. It is worth noting that in many cell-based assays measuring drug effects on virus titer, the antiviral activity is cell-type dependent, and there is also variability depending on which virus strain is used. Recent, unpublished results, reported as a preprint, suggest that imatinib inhibits SARS-CoV-2 in vitro, among 17 other FDA-approved drugs with IC50 values similar to those observed for SARS-CoV and MERS-CoV; concentrations showing antiviral activity were not cytotoxic (BioRxiv, 2020, 10.1101/2020.03.25.008482)"}

2_test

{"project":"2_test","denotations":[{"id":"32778962-24841273-84130550","span":{"begin":202,"end":204},"obj":"24841273"},{"id":"32778962-29557770-84130551","span":{"begin":465,"end":467},"obj":"29557770"},{"id":"32778962-27466418-84130552","span":{"begin":470,"end":472},"obj":"27466418"},{"id":"32778962-27466418-84130553","span":{"begin":626,"end":628},"obj":"27466418"},{"id":"32778962-24841273-84130554","span":{"begin":938,"end":940},"obj":"24841273"},{"id":"32778962-27466418-84130555","span":{"begin":943,"end":945},"obj":"27466418"}],"text":"The ABL inhibitors, imatinib and dasatinib, were identified in a screen as inhibitors of both SARS-CoV and MERS-CoV replication, and nilotinib was identified as an inhibitor of only SARS-CoV, in vitro (27). Investigation of the mechanism for imatinib against SARS-CoV and MERS-CoV revealed inhibition of the early stages of the virus life cycle, and inhibition of viral replication through blocking the fusion of the coronavirus virion with the endosomal membrane (28) (29). Importantly, authors show that targeted knockdown of ABL2, however not ABL1, significantly inhibited SARS-CoV and MERS-CoV replication/entry in vitro (29). The relatively high, albeit minimally toxic, μM range concentrations of imatinib and dasatinib required to inhibit SARS-CoV and MERS-CoV in the aforementioned cell-based studies may be attributable to experimental factors such as drug resistance of the cell lines used as tools for propagating the viruses (27) (29), and thus in vivo testing would be needed to determine optimal dosing. It is worth noting that in many cell-based assays measuring drug effects on virus titer, the antiviral activity is cell-type dependent, and there is also variability depending on which virus strain is used. Recent, unpublished results, reported as a preprint, suggest that imatinib inhibits SARS-CoV-2 in vitro, among 17 other FDA-approved drugs with IC50 values similar to those observed for SARS-CoV and MERS-CoV; concentrations showing antiviral activity were not cytotoxic (BioRxiv, 2020, 10.1101/2020.03.25.008482)"}

LitCovid-PMC-OGER-BB

PMC:7417114 / 17404-18941 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7417114 / 17404-18941 JSON TXT